Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: A project of the European collaborative study group on inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 13, Issue 7, 2007, Pages 874-881

  Odes, Shmuel ^a   Friger, Michael ^a   Vardi, Hillel ^a   Claessens, Greet ^b   Bossuyt, Xavier ^b   Riis, Lene ^c   Munkholm, Pia ^c   Wolters, Frank ^d   Yona, Hagit ^a   Hoie, Ole ^e   Beltrami, Marina ^f   Tsianos, Epameinondas ^g   Katsanos, Kostas ^g   Mouzas, Ioannis ^h   Clofent, Juan ⁱ   Monteiro, Estela ^j   Messori, Andrea ^k   Politi, Patrizia ^l   O'Morain, Colm ^m   Limonard, Charles ⁿ   Russel, Maurice ^o   Vatn, Morten ^p   Moum, Bjorn ^q   Stockbrugger, Reinhold ^d   Vermeire, Severine ^b   more..

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Section for Gastroenterology   (Norway)

^f S MARIA NUOVA HOSPITAL   (Italy)

^g UNIVERSITY OF IOANNINA   (Greece)

^h UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

ⁱ UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^j HOSPITAL DE SANTA MARIA   (Portugal)

^k CAREGGI UNIVERSITY HOSPITAL   (Italy)

^l CREMONA HOSPITAL   (Italy)

^m ADELAIDE AND MEATH HOSPITAL   (Ireland)

ⁿ MAASTRICHT UNIVERSITY   (Netherlands)

^o MEDISCH SPECTRUM TWENTE   (Netherlands)

^p UNIVERSITY OF OSLO   (Norway)

^q AKER UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Anti Saccharomyces cerevisiae antibody (ASCA); Cost of disease; Crohn's disease; Gly908Arg; NOD2 CARD15 mutations

Indexed keywords

ANTIBIOTIC AGENT; ARGININE; BUDESONIDE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; FUNGUS ANTIBODY; GLYCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LEUCINE; MESALAZINE; SACCHAROMYCES CEREVISIAE ANTIBODY; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; ENTERITIS; FEMALE; GENE MUTATION; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES, FUNGAL; CROHN DISEASE; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; ISRAEL; MALE; MIDDLE AGED; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; PROSPECTIVE STUDIES; SACCHAROMYCES; SURGERY;

EID: 34547618974     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20122     Document Type: Article

References (34)

1. Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease World J Gastroenterol. 2005;11:3971-3979.
2. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
3. Chamaillard M, Iacob R, Desreumaux P, et al. Advances and perspectives in the genetics of inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2006;4:143-151.
4. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
5. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl):5A-36A.
6. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688.
7. Annese V, Andreoli A, Andriulli A, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease - an IG-IBD study. Am J Gastroenterol. 2005;100:84-92.
8. Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet. 2002;71:74-83.
9. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004;99:2393-2404.
10. Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol. 2004:2:1003-1009.
11. Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying NOD2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005;242:693-700.
12. Vind I, Vieira A, Hougs L, et al. NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotype-phenotype analysis in Danish and Portuguese patients and controls. Digestion. 2005;72:156-163.
13. Gazouli M, Zacharatos P, Mantzaris GJ, et al. Association of NOD2/ CARD15 variants with Crohn's disease in a Greek population. Eur J Gastroenterol Hepatol. 2004;16:1177-1182.
14. Cruyssen BV, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn's disease patients. Clin Exp Immuno. 2005;140:354-359.
15. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53:1117-1122.
16. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
17. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690-697.
18. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;170(Suppl):2-6.
19. Wolters FL, van Zeijl G, Sijbrandij J, et al. Internet-based data inclusion in a population-based European collaborative follow-up study of inflammatory bowel disease patients: description of methods used and analysis of factors influencing response rates. World J Gastroenterol. 2005;11: 7152-7158.
20. Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120:827-833.
21. Odes HS, Vardi H, Friger M, et al. Cost-analysis and cost-determinants in a European inflammatory bowel disease inception cohort with 10 years follow-up evaluation. Gastroenterology. 2006;131:719-728.
22. Drummond M, McGuire A, eds. Economic Evaluation in Health Care. Oxford: Oxford University Press; 2001.
23. Laghi L, Costa S, Saibeni S, et al. Carriage of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn's ileal disease. Aliment Pharmacol Ther. 2005;22:557-564.
24. Ferraris A, Torres B, Knafelz D, et al. Relationship between CARD15, SLC22A4/5, and DLG5 polymorphisms and early-onset inflammatory bowel diseases: an Italian multicentric study. Inflamm Bowel Dis. 2006; 12:355-361.
25. Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003;9:281-289.
26. Riis L, Vind I, Vermeire S, et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis. 2007;13:24-32.
27. Annese V, Andreoli A, Andriulli A, et al. Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol. 2001;96:2407-2412.
28. Teml A, Kratzer V, Schneider B, et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol. 2003;98:2226-2231.
29. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232-1236.
30. Damoiseaux JG, Bouten B, Linders AM, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J Clin Immunol. 2002;22:281-288.
31. Russell RK, Drummond HE, Nimmo EE, et al. Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis. 2005;11:955-964.
32. Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian Tertiary Care University Hospital. Am J Gastroenterol. 2000;95:677-683.
33. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53:1471-1478.
34. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2nd ed. 1997.